Omnicell (NASDAQ:OMCL) and Privia Health Group (NASDAQ:PRVA) Head to Head Survey

Privia Health Group (NASDAQ:PRVA) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Privia Health Group and Omnicell, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0	3	12	0	2.80
Omnicell	1	1	6	0	2.63

Privia Health Group currently has a consensus target price of $30.93, suggesting a potential upside of 33.77%. Omnicell has a consensus target price of $58.50, suggesting a potential upside of 61.02%. Given Omnicell’s higher possible upside, analysts plainly believe Omnicell is more favorable than Privia Health Group.

Institutional and Insider Ownership

94.5% of Privia Health Group shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 5.7% of Privia Health Group shares are held by insiders. Comparatively, 2.5% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Privia Health Group has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.85, suggesting that its stock price is 15% less volatile than the S&P 500.

Profitability

This table compares Privia Health Group and Omnicell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Privia Health Group	1.08%	3.06%	1.77%
Omnicell	0.17%	3.00%	1.81%

Valuation & Earnings

This table compares Privia Health Group and Omnicell”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$2.12 billion	1.37	$22.92 million	$0.17	136.00
Omnicell	$1.18 billion	1.39	$2.05 million	$0.04	908.25

Privia Health Group has higher revenue and earnings than Omnicell. Privia Health Group is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Summary

Privia Health Group beats Omnicell on 9 of the 14 factors compared between the two stocks.

About Privia Health Group

Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia.

About Omnicell

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.